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ABSTRACT 
Introduction 
HIV/AIDS has remained a huge burden. It is still affecting large population of people globally 
with mortality of over 35 million people. South Africa is the most affected country. Substantial 
progress has been made in HIV antiretroviral therapy which is now capable of suppressing viral 
replication and prevent transmission. Great efforts and significant successes have been recorded 
in the fight against HIV/AIDS especially in South Africa. With effective medications, PLWH now 
have increased longevity, this makes them susceptible to chronic diseases like diabetes. The burden 
of diabetes is also high in KwaZulu-Natal, which also comes with its attendant complications. 
Despite the progress made, the scourge of HIV/AIDS and diabetes still persists. Hence this study 
aimed to evaluate the management of HIV/AIDS and diabetes as a comorbid condition, and to 
determine factors that contribute to patient outcomes.  
Methodology 
The study was conducted in 4 HIV clinics attached to Public Sector Hospitals in the eThekwini 
Metro of Kwazulu-Natal (KZN) South Africa after obtaining ethical approval. A total of 1,203 
adult, non-pregnant patients living with HIV and were receiving antiretroviral therapy for at least 
6 months between 2005 and 2019 were randomly selected and recruited in the study after obtaining 
written consent from them. Data was collected using questionnaire and from patient chart. The 
statistical package for social sciences (SPSS) software version 26 was used to analyze the data 
using descriptive statistics, Chi square and logistic regression. Results were presented, discussion 
and conclusion were made as appropriate. 
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Results 
There were 770 (64%) females and 405 (33.7%) males included in this study, with 29 to 48 years 
as the largest age group (60.2%). Clinicians prescribed the recommended add regimens in all cases. 
TDF + FTC + EFV was the most recommended regimen at 65%. On the average 43.85% of HIV 
patients were initiated on ART at CD4 count <200 cells/µL. Male gender and baseline CD4 count 
were the predictors of ART regimen changes. 
It was found that 40.8% of PLWH on ART were virally suppressed. The probability of achieving 
viral suppression was significantly less in younger patients, the less educated and those with 
baseline CD4 cells count less than 200cells/µL, while the likelihood of achieving viral suppression 
was about 4 times higher for those that received encouragement from family to adhere to ART. 
The prevalence of immunologic failure among PLWH on ART was 8.6 % (CD4 cell count <200 
cells/µL). CD4 cells count outcome was statistically significantly associated with gender, poor 
adherence to ART and baseline CD4 cells count. The probability of immunologic decline for those 
who did not strictly adhere to ART was more than 3 folds higher than those who adhered to ART; 
and the probability of immunologic failure was more than 8 folds higher for those who had baseline 
CD4 cells <200 cells/µL than those who had baseline CD4 cells ≥200 cells/µL. 
The prevalence of diabetes among PLWH on ART was 9%. Over 47% of those who had diabetes, 
had uncontrolled blood sugar, with a mean fasting blood sugar (FBS) of 11.7 mmol/L. The 
predictors of diabetes among PLWH on ART were, gender and age. Male PLWH had 65% less 
chances of having diabetes and those who were between the ages of 18 and 48 years were 88% 
less probable to have diabetes compared to those who were older than 48 years.  
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Conclusion and Recommendations 
Clinicians adhered to the national treatment guidelines, but significant percentage of the patients 
were initiated on ART late resulting in poor outcome. Those who test positive for HIV should be 
informed on the benefits of initiating ART early, the possible consequence of late initiation of 
ART and Clinicians must ensure everyone who needs ART is offered one without delay. 
The prevalence of immunologic failure was 8.6%. Predictors to immunologic failure were non-
adherence and late initiation of ART (CD4 cells <200 cells/µL). 
Prevalence of viral suppression was low (40.8%). The chances of virological failure was higher 
among younger, less educated, patients who started ART late (<200cells/µL) and patients who 
received encouragement from family to adhere to ART. Young PLWH should be regularly 
counselled on the benefits of adherence to ART, those that are not educated should be taught in 
languages they best understand, and pictorial illustrations should be used for counselling and 
family members should be involved in the follow up and encouragement of patients. That should 
be done with the permission of patients. 
The prevalence of diabetes among PLWH was high (9%) and 47% of these did not have glyacemic 
control (mean FBS was 11.7 mmol/L). The predictors were male gender and older age. Those who 
test positive to HIV should also be screened for diabetes before commencement of ART and 
treatment for diabetes should be initiated as ART is initiated and blood sugar should be monitored 
regularly to ensure glycaemic control, which is essential for the prevention of diabetic 
complications. 
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CHAPTER 1 
INTRODUCTION 
HIV/AIDS is a health scourge that is still a heavy burden of the 21st century. It has continued to 
affect large population globally. From the onset of the epidemic, over 70 million people have been 
infected, the mortality is in the range of 35 million people. 1 The population within the productive 
age bracket of 15 to 49 years of age are the most affected.1 
Sub-Saharan Africa, which has a record of approximately 67% of global burden, remains the most 
acutely affected; with South Africa being the country that is most affected.1  
Diabetes Mellitus, on the other hand, is a protracted non-infectious disease. It has acute and chronic 
complications, especially without the right management. It results in complications such as 
retinopathy, neuropathy, peripheral arterial diseases, and the diabetic foot, which can lead to 
amputations and cardiovascular diseases, among others. 2,3  
The occurrence of diabetes mellitus is rising at a disturbing rate, particularly in developing 
countries, with South Africa having the highest recorded cases; besides the larger (over 70%) 
population of the undiagnosed.4, 5  
1.1 Background and Literature Review 
Human immunodeficiency virus (HIV) is carried in the blood. It is mainly acquired via sex, 
intravenous medication tools sharing, as well as transmission from mother to child, this can happen 
in the course of birth or breastfeeding. HIV disease is brought about by infection with the 
retroviruses HIV-1 or HIV-2. 
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HIV-2 has a little bit lower transmission risk. People who are have HIV-1 are likely to have higher 
viral load than persons who have HIV-2.6,7 Higher viral load is linked with an accelerated 
deterioration to AIDS in persons with HIV-1.8,9  
The prevalence of HIV-2 in the developed world is very low; therefore research, vaccine, and 
development of drug have been concentrated on HIV-1. Infections with HIV have affected Sub-
Saharan Africa (SSA) more, compared with other regions of the world. Non-communicable 
diseases (NCDs) have become more important in-hospital admissions and mortality globally. 
Among other NCDs in affected populations in both developed and developing countries, diabetes 
mellitus has become the most concern.10  
1.2 Phases of HIV Infection  
Acute Seroconversion  
The rapid incidence of plasma viremia with widespread virus spread is seen in humans 4 to 11 
days after the virus' mucosal entry. There is no fixed synthesis site, but the virus appears to 
incorporate into active transcription areas, likely because these areas have more open chromatin 
and DNA that is more readily accessible.11,12 This severely hinders the host's eradication of the 
virus, as latent proviral genomes can stay without immune system detection and cannot be targeted 
by antivirals. During this process, the infection is discovered and a proviral reservoir is 
developed.13,14 This reservoir consists of intensely infected cells, usually macrophages, and tends 
to increasingly discharge viruses. Some of the viral discharge replenish the reservoir, creating 
some more effective infection. As calculated by DNA polymerase chain reaction (PCR), the pro-
viral reservoir appears quite stable. Though it does decline with combative antiviral therapy, the 
half-life is such that eradication is not a prospect. The pro-viral reservoir scale corresponds with 
the steady-state viral load and is associated with the anti-HIV CD8 + T-cell reaction. Combative 
3 
prompt treatment of severe infection can reduce the burden on the provirus. Mostly in newly 
infected cases, the viral load is excessive, and the number of CD4 + T-cells suddenly drops. With 
the production of anti-HIV antibodies and CD8+T-cell responses, the viral load decreases to a 
steady-state, and the CD4+T-cell count rises to levels within the reference range, albeit slightly 
lower than before infection. Seroconversion can take several months to complete, some weeks. 
Symptoms can include fever, flu-like illness, lymphadenopathy and rash during this time. For 
about half of all people infected with HIV, such symptoms occur.15  
Asymptomatic HIV Infection 
People infected with HIV at this point of infection show few to no signs or symptoms for a few 
years to a decade or more. Viral replication continues throughout this period,16 and the immune 
response to the virus is both favourable and strong. In certain cases, chronic systemic 
lymphadenopathy is an obvious symptom of infection. This rate of decrease is related to, but not 
easily presaged by, the steady-state viral load. It is reported that late initiation of therapy results in 
less effective therapy response and a lower degree of immune reconstitution. 
AIDS 
Once the immune system has been amply compromised to begin leading to severe opportunistic 
infections, the patient is considered to have AIDS. A CD4 + T-cell count of less than 200 / μL is 
often used as an criterion for the diagnosis of AIDS for surveillance purposes in the United States, 
however some opportunistic infections occur when CD4 + T-cell counts are greater than 200 /μL, 
and some individuals with a CD4 count lower than 200/μL may stay relatively healthy. 
Numerous opportunistic infections and conditions are used to identify when HIV infection has 
advanced to AIDS. The overall prevalence of these infections and conditions varies from rare to 
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common but they are all uncommon or mild in immunocompetent people. AIDS can be recognized 
if one of these is serious or chronic in a person diagnosed with HIV and there are no other 
explanations for immune suppression. 17  
1.3 CD4 Count and Viral Load 
Regardless of the clinical and CD4 count, antiretroviral therapy should be started in children, 
adolescents, pregnant and breastfeeding women, and adult persons living with HIV.18 (WHO, 
2017). With 4,4 million people taking treatment by 2018, this has made South Africa the biggest 
ART program. After ART treatment initiation, testing of viral load should be carried out every 6 
and 12 months, then every 12 months after that. As the favoured mode of diagnosing and validating 
treatment failure, WHO highly recommends viral load.18 In a period of 4-8 weeks of treatment, a 
clinical goal of 1-2-log reduction should be reached; without achieving suppression or reduction 
of the viral load, it should be adjudged as to be drug resistance.19  
1.4 History of HIV  
HIV disease was first identified in San Francisco and in New York City in 1981. Some young 
homosexual men presented with opportunistic infections usually associated with extreme immune 
deficiency at the time: pneumocystis pneumonia (PCP) and Kaposi aggressive sarcoma.20  
HIV remained unknown for the next 2 years.21 Chronic drug abuse, lifestyle and other infection 
causing agents, were considered as factors during that period.22 In the absence of testing, the 
epidemy of HIV spread fast and quietly. 
Nonetheless, cogent clinical effects were obtainable before the disease was well-known to society; 
for example, just a single incident of Pneumocystis pneumonia, specifically not related to immune 
suppression was diagnosed in the US from January 1976 and June 1980, before HIV was identified. 
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There were 42 similar diagnoses made in 1981 alone; By December 1994, the CDC had already 
reported 127,626 cases of PCP with HIV infection as the sole cause of immune suppression. 
Kaposi sarcoma is also up to 30,000 times more probable to occur in people with HIV than in 
people who were not immunocompromised.23  
1.5 The Stigma of HIV Infection 
Much stigma has been related to HIV infection, because the virus is generally associated with 
sexual acquisition and implies sexual promiscuity. This stigma led to the discrimination and 
rejection of HIV infection screening. There is stigma also as a result of fear of getting infected 
through casual contact with a HIV infected person. 
These behaviors are not right because without sexual contact or contact with blood, HIV is poorly 
transmissible. In addition, the likely life expectancy of HIV-infected patients that get treatment is 
high. HIV is not transmitted in the course of casual contact and easily destroyed by simple cleaning 
agents. Much of the fear about HIV infection is because it is incurable and the gradual immune 
failure and subsequent premature mortality in those not receiving treatment.15  
1.6 AIDS Denial 
A small but vocal faction, inclusive of some scientists, keep on the argument that there is no HIV, 
or that HIV does not lead to AIDS, and that the HIV tests cannot be trusted or that the treatments 
are toxic. This misreport is, for the most part, as a result of lack of understanding of the scientific 
literature, purposive distortion, or compelling falsehood rooted in pseudoscientific dissention. 
In the scientific literature and public symposium, all of the variances advanced by these dissidents 
were discussed and disproved and tested and rebuffed in the legal system. However, they remain 
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resolute, and these kinds of opinions can negatively affect people who are unavoidably at risk of 
exposure to HIV infection or who refuse to accept therapy for their advancing infection. 
Likewise, political denial and apathy have doubtlessly resulted in momentous damage. Various 
governments in countries with high HIV infection rates acceded gradually that they had an HIV 
epidemic, and at the beginning rejected, for example, South Africa initially rejected that AIDS was 
even a problem, then that the disease was as a result of infection; and, that antiretroviral therapy 
was efficacious in the treatment of HIV infection and holding off MTCT. Now changes have 
occurred, but they were apathetic, and it cost many thousands of lives.15  
1.7 Epidemiology 
1.7.1 Global 
As reported by the Joint United Nations Programme on HIV/AIDS24 (UNAIDS 2019), in 2018, 
about 37.9 million persons were living with HIV worldwide. The global HIV prevalence among 
adults was 0.8%. UNAIDS estimates that about 21% of the persons infected with HIV do not know 
they have the infection.24 In 2018, 770,000 people died as a result of illnesses related to AIDS.24  
Large proportion of persons living with HIV (68%) live in sub-Saharan Africa, mostly in low- and 
middle-income countries. 20.6 million of this population live in East and Southern Africa, with 
800,000 new HIV infections in 2018.24 In 2018, there were approximately 1.7 million new 
infections.24 Young women are notably susceptible,, with approximately 6,200 new infections 
occurring in this group weekly.25 In sub-Saharan Africa, 80% of new infections are among girls 
aged 15-19, and young women aged 15-24 are twice as probable to be living with HIV as men. 
More than 35% of women globally experienced physical and sexual abuse at some point. Women 
who experience abuse in some regions are one and a half times more predisposed to eventually be 
diagnosed with HIV.  
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1.7.2 South Africa 
The HIV epidemic started spreading in the early 1990s in South Africa.26 having the world's largest 
HIV epidemic, of the 37.9 million people living with HIV in 2018, approximately 7.7 million (over 
20%) were in South Africa alone.24 South Africa accounts for 33% of all new HIV infections in 
Southern Africa27, 14% of new infections worldwide in 2018. 
South Africa has taken giant strides in managing the HIV epidemic; it has the world's largest 
antiretroviral therapy (ART) programme and has mainly, for the most part, financed from its 
domestic capital. The nation spent over $1.34 billion in running its HIV services in 2015.27 The 
ART programme was relatively successful as it led to a boost in life expectancy to 67.7 years in 
2015.28  
Nonetheless, the prevalence of HIV among the general population remains high (20.4%), even 
though it differs appreciably between regions.27 For example, the prevalence is set at an estimate 
of 5.6% in the Western Cape and 6.8% in Northern Cape.29 with the prevalence of 12.2% in 
KwaZulu-Natal.30 And mortality due to AID-related illnesses was 71,000 in 2018.24  
Regardless of the giant strides made in South Africa to combat the HIV epidemic with some 
meaningful progress, the target of achieving the vision 90-90-90 by 2020 is not successful, this 
makes it essential to investigate the likely factors contributing to the slow progress as well as 
treatment failure in some. 
Also, as more people with HIV who adhere to treatment live longer, non-chronic communicable 
diseases become common among PLWH. One cogent example of such diseases is diabetes. 
Diabetes is particularly important because South Africa is among the highest prevalent nations in 
Africa. The convergence of HIV and diabetes in same patients makes it crucial to investigate the 
8 
extent and the risk factors causing the comorbidity, especially as data on the prevalence and risk 
factors of diabetes in PLWH in KwaZulu-Natal is limited. 
1.8 Complications of diabetes  
1.8.1 Diabetic Neuropathy 
Diabetic peripheral neuropathy is defined as “the presence of symptoms and signs of peripheral 
nerve dysfunction in people with diabetes after exclusion of other causes.”31,32 Feature of 
neuropathies is prolonged loss of function of nerve fiber. Neuropathies gravely decrease patients’ 
quality of life (QOL) and can introduce severe secondary complications such as falls, fractures, 
foot ulcers, cardiac arrhythmias, amputations, and death.33A study carried out in India showed a 
meaningful association in peripheral arterial disease (PAD) patients to be with complications like 
retinopathy and neuropathy. PAD is affecting diabetic patients; age as one of the host factors also 
the duration of diabetes in the patient. PAD comes with many risks to diabetic patients, which may 
bring about lower limb amputations. PAD patients have a higher possibility of having a stroke, or 
even death may occur. 
1.8.2 Diabetic Foot Infections 
Infections of the foot commonly occur in patients with diabetes who are susceptible to such 
infections due to altered vascular supply. Local trauma and compression, mostly combined with 
numbness as a result of neuropathy, along with microvascular disease, can give rise to diverse 
different diabetic foot infections ranging from simple to severe ones. 
Treatment of infections in diabetic patients is challenging. This is because they have poor 
microvascular circulation, which prevents phygocytic cells from reaching infected tissues. They 
can also have linked infections affecting bone and tissue called fetid foot, peripheral macrovascular 
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diseases as well as peripheral microvascular and capillary disease with gangrene.35,36,37,38,39 In 
addition, the number of people having diabetes among HIV positive patients is also increasing. 
This is by reason of factors such as an increase in life expectancy owing to the availability of 
antiretroviral drugs as well as metabolic side effects of some antiretrovirals, which are implicated 
in causing insulin resistance.40,41 This makes diabetes a significant co-morbidity in persons living 
with HIV, which requires a critical attention and an integrated management strategy.  
1.9 Management of HIV 
The guideline for the management of HIV has gone through a metamorphosis. Since the first 
antiretroviral Zidovudine, was approved in 1987, there have been repeated alteration in the 
antiretroviral treatment guidelines, as more drugs are found. The current guideline requires the use 
of three antiretroviral drugs that belong to different classes (HAART).46  
There have been adjustments also in pill burden, starting with a Zidovudine the only regimen to 
multi-dose regimen to the current fixed-dose regimen.47  
The guideline for the commencement of treatment has also undergone changes; at the beginning, 
patients were started with ART when they had CD4 count ≤ 200 cell/µL, then switched to CD4 
count ≤ 500 cell/µL, but now clinicians are encouraged to treat everyone that tests positive to the 
virus.48  
While all these guidelines are developed to achieve maximum therapeutic results in managing 
HIV/AIDS, a successful antiretroviral therapy, to a great extent, depends on patient adherence to 
medications, clinician’s adherence to guidelines, amongst other factors. Several suitable 
approaches could be employed to enhance medication adherence.49,50  
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1.10 Description of the Core Research Problem and its Significance 
Despite the availability of effective ART and having the biggest anti-retroviral therapy universally, 
the strain of HIV remains utmost in South Africa, with Kwazulu-Natal carrying the highest burden, 
41,42,43,44 and many patients not attaining viral suppression. Also, many diabetic patients are not 
achieving enough glycaemic control at both private and public health institutions.5,45,2 (Pillay, 
Adous & Mahomed, 2015; Amod, Riback & Schoeman, 2012; Pillay et al. 2016) 
1.11 The Rationale of the Study 
Considering the huge resources spent in providing anti-retroviral therapy to those living with HIV, 
the provision of Post Exposure Prophylaxis to people who have been exposed to the risk of 
infection; as well Pre-Exposure Prophylaxis for those at high risk, it is crucial to survey the various 
factors that could impact on patient management outcomes with the view to finding the likely 
reasons for the failure to achieve optimal treatment outcomes for many of those on ART.   
1.12 Research questions, aim, and objectives 
1.12.1 Research Questions 
The main research question: Do clinician factors such as adherence to HIV management protocol, 
patient factors such as adherence to ARVs, and diabetes affect HIV management outcomes, and 
how do they affect it? 
The specific research questions are: 
➢ Do clinicians adhere to the HIV management protocol? 
➢ What are the patient factors that are associated with HIV management outcomes? 
➢ What are the effects of these patient factors on HIV management outcomes? 
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➢ What is the prevalence of diabetes among PLWH? 
➢ What are the predictors of diabetes in PLWH? 
1.12.2 Aims and Objectives of the Study 
This study aimed to assess adherence to HIV management protocols, effects of patient factors, and 
clinician factors on HIV patient management outcomes. Also, to determine the prevalence and 
predictors of diabetes mellitus among persons living with HIV. 
1.12.3 The specific objectives of the study were: 
➢ To assess clinician’s adherence to the HIV management protocols 
➢ To determine patient factors that could influence management outcomes such as viral 
suppression and immunological recovery. 
➢ To determine the effects of patient factors on management outcomes such as viral 
suppression and immunological recovery. 
➢ To evaluate the prevalence and predictors of diabetes mellitus among PLWH 
1.13 Research Methodology 
A detailed methodology is included in each of the papers/manuscripts that appear in chapters 2, 3, 
4 and 5. 
1.13.1 Study Design 
This study was a retrospective and prospective study, based on analysis of sampled PLWH, which 
used questionnaires and patient hospital files for data. 
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1.13.2 Study setting and data source  
The study was conducted at the HIV clinics of four public sector hospitals in the eThekwini health 
district of KwaZulu-Natal that are situated at former designated racial settlements. Random 
sampling technique was used to obtain data from persons living with HIV (PLWH) who have been 
on antiretroviral therapy (ART) for at least 6 months between 2005 and 2019. 
1.13.3 Inclusion criteria 
➢ Persons living with HIV (PLWH) who may or may not have diabetes 
➢ Receiving ART for at least 6 months between 2005 and 2019. 
➢ Adults (18 years and above) 
➢ Male and female (not pregnant) 
1.13.4 Exclusion criteria 
➢ Persons living with HIV (PLWH) who are below 18 years. 
➢ Persons living with HIV (PLWH) who started receiving ART before 2005 or have not been 
on ART for at least 6 months. 
➢ Pregnant women 
➢ Persons who were initially included but opted out of the study in the course of data 
collection. 
1.13.5 Sampling technique and sample size 
Random sampling technique was used to avoid bias and to obtain a sample that is a true 
representation of the population of the study. This was achieved as follows:  PLWH were 
approached, the purpose of the study was explained to them and their consent to participate in the 
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study was requested by reading out the BREC consent form for those who could not read, in a 
language of their choice and those who could read were given the form to read.  Each person who 
consented to participate in the study by signing the consent form was asked to pick randomly, 
squeezed piece of paper in a pool of small pieces of paper on which the letters Y or N was written, 
the papers were squeezed and mixed. Anyone who happened to pick a paper with letter Y was 
included in the study, provided he or she met the inclusion criteria. 
The minimum sample size for this study was calculated as 249 participants per hospital, and this 
gave a total of 996 participants from the 4 hospitals. 
The following statistical parameters were used to arrive at the minimum sample size: Odds ratio = 
1.25, type 1 error = 0.05, type 2 error = 0.2 and statistical power = 0.80. Assuming a population 
variance of 1 and a population mean of 0 (normal distribution). A minimum sample size of 996 
was determined for the 4 hospitals with a critical Z value = 1.96. 
However, the actual sample size collected was 281, 286, 345, and 291 from the 4 hospitals, 
respectively, giving a total sample size collected as 1203 
1.13.6 Data collection 
Data collection took place between the period of 3rd October 2018 and 10th August 2019. Data was 
collected using two instruments, questionnaire and patient chart, which were designed using MS 
Word 2016. 
The questionnaire was designed to obtain information on patient demographics such as name, 
gender, age among others, and patient factors such as education level, adherence to medications, 
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consumption of alcohol, use of supplements, use of traditional medicine, patients’ knowledge of 
the disease, patients’ attitude towards treatment among others. 
The questionnaire was pretested among a few of the persons living with HIV (PLWH) who were 
attending ARV clinics. The pretesting was done to ensure the validity and reliability of the 
questionnaire to obtain accurate responses from the respondents. The pretested questionnaires that 
were in isiZulu and English languages were administered according to the language of choice of 
each respondent and were retrieved after the respondents completed them. Those who participated 
in the pretest were not included into the main study participants during the actual data collection. 
The patient chart was used to obtain data that were relevant to the management of HIV from the 
hospital record. The data obtained included CD4 counts, viral loads, clinical stages, ARV 
commencement dates, ARV regimens used. Adverse effects experienced, diabetes status, among 
other information. 
1.13.7 Data analysis 
Data analysis was performed using the Statistical Package for Social Sciences (SPSS) version 26 
using descriptive statistics; frequencies of all categorical variables were obtained. A chi-square 
test was used to determine the relationship between variables, univariate and multivariate logistic 
regressions were used to determine the relationships and the extent of relationships between 
variables as appropriate. All levels of significance were kept at p < 0.05. 
1.14 Ethics consideration 
The study obtained approval from the Biomedical Research Ethics Committee of the University 
of KwaZulu-Natal with the ethics reference number BE314/18. 
15 
1.15 Structure of the thesis 
Chapter 1: Introduction, literature review and methodology 
Chapter 2: Presentation of manuscript titled: Adherence to treatment protocols/guidelines by 
clinicians in the management of HIV, submitted to BMC Infectious Diseases for publication. 
Chapter 3: Presentation of a manuscript submitted for publication in AIDS Care and it is under 
review on ‘patient factors and viral suppression in HIV management’. The manuscript is presented 
in line with the specific guidelines of the journal. 
Chapter 4: Published paper in Ponte Journal titled: Patient factors and immunologic recovery in 
HIV management.  
Chapter 5: Presentation of a manuscript titled: Prevalence and predictors of diabetes among 
persons living with HIV, submitted to BMC Public Health for publication. 
Chapter 6: Discussion and synthesis 
                 Limitations of the study 
                  Conclusion and recommendations 
                  Annexures 
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Chapter 1 provided the background and literature review on HIV and the global epidemic, 
diabetes and HIV co-infection and the challenges associated with them globally and in South 
Africa. The rationale to do the study together with the problem statement was also included and 
concluded with its stated aims and objectives. The methodology used in the study was also 
detailed.  
 
In Chapter 2, one of the stated objectives viz ‘To assess clinician’s adherence to the HIV 
management protocols’ is presented. 
  
Adherence to HIV treatment guidelines by clinicians is critically important in order to achieve 
the desired outcomes in the management of HIV. An important first step in this study therefore 
was to ascertain if the treatment guidelines were adhered to by clinicians in the management of 
HIV in PLWH.  The findings are presented in this chapter.  
 
The chapter is presented in the format of a manuscript. 
The manuscript titled ‘Adherence to HIV Treatment Protocols by Public Sector Clinicians in the 
eThekwini Metro of KwaZulu-Natal’: A Retrospective Study’ is presented according to 
submission guidelines of BMC Infectious Diseases. 
Submission Date: 11TH June 2020.  
Manuscript Number: INFD-D-20-02030 
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Manuscript submitted to BMC Infectious Diseases 
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Chapter 2 provided information on the level of clinician’s adherence to the South African 
HIV treatment protocols, rate of late initiation of ART, most prescribed and most switched 
to ART regimen and predictors to switching from one ART regimen to another. 
 
In chapter 3, one of the objectives, that is, ‘To determine effects of patient factors on HIV 
management outcomes’ is presented (‘Viral suppression’ is the outcome presented in this 
chapter). 
 
Viral suppression is the main determinant of a successful management of HIV infection. 
Some specific patient factors such as adherence can influence this outcome despite 
clinician’s adherence to antiretroviral protocols. The findings are presented in this chapter. 
 
The chapter is presented in the format of a manuscript. 
This manuscript titled ‘Patient Factors and Viral Suppression in HIV Management’ is 
presented according to author’s guide of AIDS care journal. 
Submission Date: 11th January 2020. It is currently under review. 
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Manuscript under review 
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Chapter 3 provided information on the ‘patient factors and viral suppression in HIV 
management’, thus percentage of PLWH on ART who achieved viral suppression, patient 
factors significantly associated with viral suppression and predictors to achieving viral 
suppression is presented. 
 
In chapter 4, another aspect of the stated objective as in chapter 3 viz ‘To determine patient 
factors on HIV management outcomes’ is presented (‘immunologic recovery’ is the outcome 
presented).  
 
Immunologic recovery usually occurs as viral suppression is achieved. Immunologic 
recovery is indicated by increase in CD4 cell counts to normal range. This prevents the 
presence of opportunistic infections which are a hallmark of immune suppression.  
 
Some specific patient factors may influence how well and sustained CD4 cells count 
increases resulting in good immunologic recovery. The findings are presented in this chapter. 
 
. 
This manuscript titled ‘Patient Factors and Immunologic Recovery in HIV Management’ has 
been published in PONTE Journal. 
Publication Date: May, 2020 
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Chapter 4 provided information on the ‘effects of patient factors on immunologic recovery’, 
thus, prevalence of immunologic failure among persons living with HIV on ART, patient 
factors significantly associated with immunologic recovery and predictors of immunologic 
failure among persons living with HIV were highlighted.    
 
In chapter 5 the final stated objective viz ‘To Evaluate the Prevalence and Predictors of 
Diabetes among PLWH’ is presented. 
 
Successful management of HIV increases longevity among PLWH, however co-morbidities 
like chronic non-communicable diseases [NCD] sometimes interfere with positive health 
outcomes. One such NCD is diabetes. Therefore, evaluating the prevalence and the 
predictors of diabetes among PLWH is an important step in understanding the challenge of 
such comorbidities and managing them. The findings are presented in chapter 5. 
 
The manuscript titled ‘Prevalence and predictors of Diabetes Mellitus among Persons Living 
with HIV (PLWH)’ is presented according to the submission guidelines of BMC Public 
Health. 
Manuscript Number: PUBH-D-20-03462 
Submission Date: 11TH June 2020.  
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CHAPTER 5 
Manuscript submitted to BMC Public Health   
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Chapter 5 provided information on the prevalence and predictors of diabetes mellitus among 
persons living with HIV (PLWH), thus highlighting the prevalence of diabetes among PLWH, 
association between the prevalence of diabetes and commencement of ART, glycemic control 
among PLWH and the predictors of diabetes among PLWH.    
 
In chapter 6 the thesis is discussed, synthesized, concluded with subsequent recommendations. 
The limitation of the study is also included in this chapter. 
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CHAPTER 6 
DISCUSSION/SYNTHESIS 
This study investigated and reported on the adherence of clinicians to HIV treatment guidelines, 
patient factors that could influence HIV management outcomes and their specific effects on the 
outcomes, as well as determined the prevalence, treatment outcomes and predictors of diabetes 
among PLWH. 
Clinicians’ adherence to treatment guidelines including regimen change. 
Antiretroviral treatment guidelines were developed to guide HIV/AIDS clinicians on the use of 
ARV therapy in order to optimize patient care.53 The metamorphosis in the HIV treatment 
guidelines over the few decades shows the evolving challenges in the field of antiretroviral 
therapy.52  
The finding  that the average annual prevalence of ART initiation at CD4 cell count <200 cells/µL 
was 40% from 2005 to 2018 is in contrast to a study in Thailand where 19% had a baseline CD4 
count below 200 cells/µL.54  This is concerning because as far back as 2013, the South African 
HIV treatment guidelines had  moved away from recommending late initiation of ART (at CD4 
count ≤200 cells/µL),  to initiating ART early at CD4 ≤350 from 2013 to 2015. The current 
recommendation is ‘Treat all’, that is, initiate ART for everyone who tests positive for HIV.55 
Early initiation of ART in persons who tests positive to HIV has been proven to improve treatment 
outcomes such as viral suppression, prevention of transmission, reduction in morbidity and 
mortality.56,57 It is therefore not enough to have effective medicines available or test widely but 
also to initiate ART early for everyone who tests positive for HIV, in other to optimize treatment 
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outcomes, prevent transmissions and to reduce morbidity and mortality.58,59,60 This is essential to 
win the war against HIV/AIDS in South Africa and globally. 
Prescribers adhered to treatment guidelines with respect to the recommended ARV regimens, and 
prescribed ART regimens constituting 2 NRTIs with either a NNRTI or a PI.61,62,63,53,64 This is 
excellent, however the problem of late initiation of ART must be overcome to derive the potential 
optimal treatment outcomes as a result of using the right drugs combinations.  
The most prescribed first line ART regimen was TDF/FTC/EFV (65%) as well as the most 
switched to regimen (63.8%). This could be due to the tolerability and high rate of viral suppression 
of this regimen as shown by other studies.65 It also shows the adherence to the guidelines by 
clinicians in prescribing it as the first line, first choice regimen as recommended.62,63,53,64. 
An interesting finding regarding switching of regimens was also made in this study. Male patients 
on ART were 40% less likely to be switched from ART regimen to another (aOR = 0.60, 95% Cl= 
0.34-0.97, P-value= 0.037), a finding supported by other studies, such as the US study which found 
that females were more likely to have regimen change due to poor adherence.66 and the study on 
women from Southern Africa which also showed that females had a higher chance to change 
regimen.67 This may be due to gender-specific factors such as pregnancy as evidenced in another 
study from South Africa that found the predictors of non-adherence to ART by pregnant women 
were marital status, non-disclosure to sexual partner and family, cigarette smoking and alcohol 
use.68 Regimen change leads to less available options of ART regimen for clinicians to choose 
from for the specific patients and regimen changes that are prompted by resistance to antiretroviral 
medicine poses a public health challenge. More studies are recommended in order to better 
understand the causes and tailor treatments to minimize the chances to switch regimen by females. 
It is also necessary to come up with strategies to increase durability of initial regimens.69 
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In addition, it was found that patients on ART who had baseline CD4 count below 200 cell/µL had 
2 folds likelihood of being switched from one regimen to another (aOR = 1.99, 95% Cl= 1.18-
3.34, P-value = 0.010). This is expected, as baseline CD4 cells count has been generally shown to 
influence HIV treatment outcome.70,56 However, the problem of late initiation of ART could be 
overcome or minimized if people who test positive for HIV are initiated on ART early, as all who 
test positive are now eligible for treatment.55 
The most prominent finding in this section is that there has been consistently late initiation of ART 
(at CD4 <200 cell/µL) all through from 2005 to 2018. This must be addressed to win the fight 
against HIV/AIDS.  
Patient factors and viral suppression 
Highly active antiretroviral therapy (HAART) has made HIV a medically manageable condition 
in patients who have access to medication.71,72 
HAART has also made it possible to achieve sustained HIV suppression, eliminating the risk of 
HIV transmission.73,74,71,75,76,77  
This study found that only 40.8% of PLWH on ART achieved viral suppression, which is far below 
the third of the UNAIDS target of “90-90-90” by 2020.78 
The probability of achieving viral suppression for HIV patients on ART who were between the 
ages of 18 to 28 years old was 73% less than that of HIV patients who were older than 48 years 
old (aOR = 0.27, 95% Cl= 0.13-0.60, P-value=0.001), while for those between the ages of 29 and 
48 years old was 39% less than that of HIV patients who were older than 48 years (aOR = 0.61, 
95% Cl= 0.39-0.95, P-value=0.028). These show that viral suppression is higher amongst the older 
age groups, similar to a study by Hess and Hall in 2018.79 The lower chances of achieving viral 
suppression in younger patients may be due to lower adherence to antiretroviral medications by 
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younger patients compared to older patients. This could possibly be due to younger persons’ 
awareness that HIV infection is no longer a ‘death sentence’. However, this possible attitude could 
lead to drug resistance which is a public health concern. Another reason may be that older patients 
are more concerned about their health, overcome stigma easily, stay at home more, which results 
in better adherence to their medication hence higher rate of viral suppression. 
The finding relating to their level of education has shown that patients who had primary school 
education were 57% less likely to achieve viral suppression than those who had tertiary level 
education (aOR = 0.43, 95% Cl= 0.22-0.83, P-value=0.012), whilst patients with high school  
education were 50% less likely to achieve viral suppression than those who had tertiary level 
education (AOR = 0.50, 95% Cl=0.28-0.87. P-value=0.014). This is expected, as higher level of 
education could make an individual understand instructions and counselling better, be able to seek 
for further clarification from health professionals and trained counsellors, they could also read 
written materials that are meant to enlighten patients and the general public about HIV, its 
management and outcomes.  Another possible reason for this difference in viral suppression 
outcomes may be that the higher the education an individual has, the better the chance of being 
employed which assists them financially in managing their condition. 
HIV patients on ART, who had encouragement from family members to adhere to their 
medications were about 4 times likely to achieve viral suppression than those who did not receive 
family encouragement (aOR = 3.74, 95% Cl= 1.30-10.70, P-value= 0.014.) This finding is similar 
to another study conducted in South Africa which indicated an improved viral suppression among 
patients on ART who received community-based adherence support.80  The effect of 
encouragement from family is mediated through a variety of mechanisms such as greater 
disclosure, reduction in stigma, decrease in psychological problems, which in turn are likely to 
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increase adherence to medications.81,82 These, most likely were responsible for the desired 
outcome of viral suppression seen in these patients. 
 Furthermore, patients on ART that had baseline CD4 counts <200 cells/µL were 53% less likely 
to achieve viral suppression compared to those who had ≥200 cell/µL (aOR = 0.47, 95% Cl= 0.31-
0.70, P-value= 0.000), that is, virological failure is higher with patient who initiated ART at a 
lower baseline CD4 cell count (<200 cells/µL). This finding supports the WHO recommendation 
that ART should be initiated in everyone who tests positive for HIV irrespective of CD4 cell 
count.83 
Patient factors and immunologic recovery 
CD4 count is an important guide for the commencement and stoppage of primary and secondary 
prophylaxis against opportunistic infections such as Pneumocystic jirovecii, Cytomegalovirus and 
other opportunistic pathogens during antiretroviral therapy (ART) in patients with HIV infection. 
Prophylaxis against opportunistic infections can be stopped safely, the moment CD4 count 
increases above 500 cells/μL.85,84 
 In this study when patient specific factors were investigated it was found that, the higher the 
baseline CD4 cells count at the commencement of antiretroviral therapy was, the higher the 
percentage increase in CD4 cell count towards the reference range of 500 – 2000 cells/µL, leading 
to better chances of achieving full immunologic recovery. This corresponds with a study by 
Adewumi et al., in 2015 87. 
 The prevalence of immunologic failure (CD4<200 cells/µL) among PLWH on ART was 8.6% in 
this study. There is scarcity of data in South Africa on prevalence of immunologic failure among 
PLWH on ART. However, studies have shown that there is a pattern of decrease in CD4 cells after 
some years on ART.88,89,90  
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Patient’s age, stopping medication after being adherent for a long time (2 to 3 years) and baseline 
CD4 cells count of PLWH on ART were significantly associated with immunologic response 
(current CD4 cell count). 
After adjusting for confounders, the predictors to immunologic recovery of PLWH on ART were 
baseline CD4 cell counts, duration on treatment (ART) and non-adherence to ART (forgetting to 
take HIV medicines sometimes). 
The probability of immunologic failure for PLWH on ART who had baseline CD4 cells count 
<200 cells/μL was more than 8 folds higher that those who had baseline CD4 cells count ≥200 
cells/μL (AOR = 8.03, 95% Cl= 3.28-19.67, P-value = 0.000). This strongly supports the current 
recommendation of ‘Treat all’, rather than allowing CD4 cells count to drop before treatment 
commences.86 
There was significant association between immunologic failure and patient’s stopping medications 
after a long time (2 to 3 years) of being adherent. The probability of immunologic failure for 
PLWH on ART who did not strictly adhere to treatment (sometimes forget to take their medicines) 
was more than 3 folds higher than those who strictly adhered to their medications (aOR = 3.06, 
95% Cl=1.28-7.33, P-value = 0.012). This shows that poor adherence to ART, either occasional 
forgetfulness or a break after a long period of adherence, results in immunologic failure. This 
finding is similar to an earlier study.91 and further underscores the necessity of strict adherence to 
antiretroviral therapy by PLWH to prevent immunologic failure, achieve and maintain 
immunologic recovery as well as prevent resistance to ART, which could be a public health threat, 
as affirmed by other studies.92,91 Poor adherence has been a major cause of treatment failure, it is 
therefore extremely essential to formulate effective strategies to combat it in order to achieve 
optimum treatment outcomes in PLWH on ART. 
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Prevalence and predictors of diabetes mellitus among PLWH 
In this study the prevalence and predictors of diabetes among PLWH on ART in the eThekwini 
municipality of KZN was assessed.  
 It was important to understand the magnitude of the problem as proper management is essential, 
not only for the prevention of diabetic complications, mortalities due to the complications or for 
the improvement of quality of life but also to prevent possible negative impact on the outcomes of 
managing HIV.   
The prevalence of diabetes among PLWH on ART in KZN was 9%, this was consistent with 
findings by other studies.94,95,96,93 , this was higher than the prevalence of diabetes among the 
general population which was 5.4%.97 However, a study by Diabetes Focus eMag98 indicated that 
prevalence of diabetes among PLWH is similar to that among the general population. This 
difference in findings from different studies may be due to differences in the prevalence of diabetes 
amongst different populations. 
There was higher prevalence of diabetes among females PLWH (9.5%) than that of males (7.4%), 
similar to a study by Hernandez-Ronieu et al, in 2017.99 where it was shown that the prevalence 
of diabetes is higher in females among the general population. This also confirms our finding that 
female gender is a predictor to diabetes in PLWH, as males living with HIV were 65% less likely 
to have diabetes than females (aOR = 0.35, 95% Cl= 0.15-0.82, P-value=0.016) in this study. This 
finding is similar to other studies which indicated that females who are HIV positive are more 
likely to have non-communicable diseases (NDC) co-morbidity.100,101 Hence, all persons who test 
positive for HIV, particularly females, should be screened for diabetes and should be repeatedly 
tested at close interval while they are on ART, in order to detect diabetes early and manage them 
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accordingly, so as to avoid diabetic complications which could further increase pill burden and 
worsen morbidity and mortality due to both conditions. 
Over 60% of the PLWH were diagnosed with diabetes after the commencement of ART, however, 
there was no statistically significant association between commencement of ART and the 
incidence of diabetes mellitus. Earlier studies vary in their findings with regards to the association 
between ART and diabetes, with some studies showing similar results to this study,98 whilst other 
studies found association between ART and diabetes.102,94,95,96 While the question whether ART 
actually predisposes PLWH to diabetes or not remains debatable, people who test positive for HIV 
should be tested for diabetes before the commencement of ART and periodically thereafter.  
Almost half (47.1%) of the PLWH with diabetes in this study had uncontrolled blood sugar (Mean 
FBS of 11.7 mmol/L). This is particularly concerning, as this predisposes them to diabetic 
complications such as retinopathy, neuropathy, nephropathy among others. There is need to 
involve specialists in the management of patients with HIV and diabetes comorbidity for the 
attainment and maintenance of glycemic control 
Older age is the other predictor for diabetes among PLWH. The likelihood of diabetes for those 
older than 48 years of age was 88% compared to those that were younger than 48 years of age 
(aOR = 0.12, 95% Cl= 0.06-0.26, P-value=0.000). This is in line with other studies which showed 
that old age is a risk factor to chronic co-morbidities in PLWH.100,101 As ART increases the life 
span of PLWH, predisposing them to chronic medical conditions such as diabetes, clinicians 
should give adequate attention to diabetes in PLWH as they do to other co-morbidities. 
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Limitation of the study 
Data for 291 patients from one of the hospitals was incomplete, due to researcher not being given 
access to some of the data, despite obtaining written permission from the authorities concerned. 
However, during the analysis such missing data were accounted for by ensuring that all analysis 
that required those missing data were done by excluding that specific hospital analysis in order to 
ensure the integrity of the results. 
Conclusion and recommendations 
Though clinicians adhered to the treatment guidelines, a significant percentage of PLWH from 
2013 till 2018 were initiated late on ART (baseline CD4 count <200 cells/µL). Steps should be 
taken to ensure that those who test positive to HIV are initiated immediately on ART as long as 
possible. 
Female gender and late initiation of ART were the predictors of ART regimen change. It is 
therefore essential to develop strategies to increase the durability of initial regimens in order to 
avoid exhausting the available treatment options which would be detrimental not only to the 
patients concerned but could also be a public health challenge. 
The percentage of viral suppression was low (40.8%). Predictors to viral suppression in PLWH on 
ART were older age, higher level of education, family support and baseline CD4 count higher than 
200 cells/µL. 
Predictors to immunologic failure were poor adherence to ART and lower baseline CD4 count 
(CD4 cell count <200 cells/µL).  
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Further research is recommended to determine the reason(s) for late initiations of ART in South 
Africa. This late initiation contributes substantially to the less-than-desired outcomes. This 
continues to occur despite the recommendation by the DoH to initiate ART, immediately, a person 
tests positive for HIV. 
Prevalence of diabetes among PLWH was higher than that of the general population with 47.1% 
of them having uncontrolled blood sugar (mean FBS of 11.7 mmol/L). There is need to give 
particular attention to diabetes in PLWH as done with other comorbidities. 
Female gender and older age were predictors to diabetes among PLWH on ART. Screening for 
diabetes should be intensified among PLWH on ART. Policy makers should consider diabetes as 
a comorbidity of interest in PLWH , by making the screening of diabetes a requirement for all 
those who test positive for HIV . Screening should be done before the initiation of ART and at 
regular intervals while on ART as well as manage those patients that are found to be diabetic. 
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ANNEXURE 2: PATIENT INFORMED CONSENT FORM 
 
UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
 
 
Information Sheet and Consent to Participate in Research 
 
Date: ………………….. 
Dear Sir/Madam, 
My name is ………………………, from Discipline of Pharmaceutical Sciences, University of 
Kwazulu-Natal, Westville Campus, Durban. 0670842890, 217075064@stu.ukzn.ac.za , 
myresearchmail2017@gmail.com .  
You are being invited to consider participating in a study that involves research on ‘Evaluation of 
the management of HIV/AIDS with diabetes as a comorbid condition in public health facilities in 
the eThekwini metro of Kwazulu-natal. Defining contributory factors to patient outcomes’. The 
aim and purpose of this research is to find out how HIV patients are treated, to find out if some of 
them have diabetes and how the diabetes is treated, to find the things that patients do that affect 
their treatment. The study is expected to enroll at least 249 participants in each ARV clinic, that is 
a total of 996 participants in 4 ARV clinics in eThekwini metro of Kwazulu-natal. It will involve 
the following procedures, collection of data from people living with HIV using a questionnaire as 
well as collecting data from patient chart that is in the hospital. Then use the data collected to find 
out how patients are managed and what the outcomes are. The duration of your participation if you 
choose to enroll and remain in the study is expected to be just today. The study is funded by the 
college of health sciences, University of Kwazulu-natal. 
The study will provide no direct benefits to you. This study is hoped to show how best to manage 
HIV to achieve better outcomes.  
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number_____). 
In the event of any problems or concerns/questions you may contact the researcher at the Discipline 
of Pharmaceutical Sciences, University of Kwazulu-Natal, Westville Campus, Durban. 
0670842890, 0608225125, 217075064@stu.ukzn.ac.za , pharmumar73@gmail.com) or the 
UKZN Biomedical Research Ethics Committee, contact details as follows:  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
141 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
Participation in this research is voluntary and you may withdraw participation at any point, in the 
event you refuse to participate or withdraw from participation after you have started, you will not 
incur any penalty or loss your treatment. If you choose to withdraw from the study at any point 
while filling the questionnaire, you can notify the researcher and return the questionnaire to him. 
The researcher will terminate your participantion from the study if he discovers that you are below 
18years of age. 
You will not incur any cost because of your participation in this study. There are no incentives or 
reimbursements for your participation in this study. 
Only information that is necessary to enable the researcher to carry out this study will be collected 
from you or your chart. Your identity will not be disclosed to any one during or after this study. 
Your data will be converted into a format that will not reveal your identity and then analyzed in 
group to arrive at a conclusion. All hard copy documents such as the questionnaire and tabulated 
data will be kept in a secure locker and will be destroyed when relevant information is entered into 
statistical software for analyses. 
CONSENT  
I………………………………………………………………………………………………… 
have been informed about the study titled ‘Evaluation of the management of HIV/AIDS with 
diabetes as a comorbid condition in public health facilities in the eThekwini metro of KwaZulu-
Natal. Defining contributory factors to patient outcomes by David Mohammed Umar. 
I understand the purpose and procedures of the study. 
I have been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any 
time without affecting any treatment or care that I would usually be entitled to. If I have any further 
questions/concerns or queries related to the study I understand that I may contact the researcher at 
the Discipline of Pharmaceutical Sciences, University of Kwazulu-Natal, Westville Campus, 
Durban. 0670842890,  217075064@stu.ukzn.ac.za , pharmumar73@gmail.com. 
If I have any questions or concerns about my rights as a study participant, or if I am concerned 
about an aspect of the study or the researcher then I may contact 
142 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
____________________    ____________________ 
Signature of Participant                            Date 
____________________ _____________________ 
Signature of Witness                                Date 
(Where applicable)      
_________________ _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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ANNEXURE 4: QUESTIONNAIRE 
Dear Participant,  
Thank you for agreeing to participate in this study. 
You indicated you are taking medication for your HIV. Some individuals have identified 
many issues concerning their medicine-taking behavior and we are interested in your 
experiences. There is no right or wrong answer. Please answer each question based on your 
personal experience with your HIV medication.  
Please TICK the appropriate box 
 
1. Gender 
Male Female Transgender 
   
2. How old are you (In years)? 
 
18-23  24-
28  
 
29-33  34-
38  
 
39-43  44-
48  
 
49-53  54-
58  
 
59-63 64-
68 
Above 68 
Years 
           
3. What is your educational level? 
 
Primary school High school Tertiary level No formal 
education 
    
4. Are you employed?                        
Yes No 
  
5. When do you usually take your HIV medicine (s) every day? 
 
In the morning In the afternoon In the evening At night 
    
6. Do you sometimes forget to take your medicine for HIV?                        
Yes No 
  
7. Thinking over the past 2 weeks, were there any days when you did not take your HIV 
medicine(s)? 
Yes No 
  
8. If yes, what was the reason(s) for not taking your HIV medicine(s)?  
I forgot Too many 
people around 
I got tired of 
taking it 
Was too busy Others 
(Please 
specify) 
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9. Thinking over the past 1 month, were there any days when you did not take    your HIV 
medicine(s)? 
Yes No 
  
10. If yes what was the reason(s) for not taking your HIV medicine(s)? 
 
I forgot Too many 
people around 
I got tired of 
taking it 
Was too 
busy 
Others (Please 
specify) 
     
11. Have you ever cut back or stopped taking your HIV medicine(s) without telling your 
doctor/nurse because you felt worse when you took it? 
Yes No 
  
12. What do you mean by feeling worse? 
 
Felt nauseous Had diarrhea Had Headache Others (Please 
specify) 
    
13. Did you visit the doctor/nurse thereafter?  
Yes No 
  
14. If Yes, what did the doctor/nurse do? 
 
Treated me but did not 
change the medicines 
Treated me and changed the 
medicines 
Others (Please specify) 
   
15. When you travel or leave home, do you sometimes forget to take along your HIV 
medicine(s)? 
Yes No 
  
16. Did you take all your HIV medicines yesterday? 
Yes No 
  
17. When you feel like your symptoms are under control, do you sometimes stop taking your 
HIV medicine(s)? 
Yes No 
  
17. If yes, when do you start taking your medicines again? 
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The next 
day 
After 2 days After 5 days After 1 
week 
After 1 
month 
Others 
(Please 
specify) 
      
18. Taking HIV medicine(s) every day is a real inconvenience for some people. Do you ever 
feel inconvenienced about sticking to your treatment plan? 
Yes No 
  
19. How often do you have difficulty remembering to take all your HIV medicines? 
 
Never Once in a while Sometimes Usually All the time 
     
20. Do you take alcohol? 
Yes No 
  
21. If yes, how often do you take alcohol? 
   
Occasionally Sometimes Usually Everyday 
    
22. When do you usually take alcohol? 
 
In the morning In the afternoon In the evening Anytime 
    
23. Do you take herbal/traditional medicines? 
Yes No 
  
24. If yes, have you told your doctor/nurse that you take herbal/traditional medicine? 
Yes No 
  
25. If no, why have you not told the doctor/nurse? 
 
Afraid to tell them Did not think it 
necessary to tell 
them 
My traditional 
healer asked me not 
to tell the doctor or 
nurse. 
Others [please 
specify] 
    
26. Do you take your herbal/traditional medicines and your HIV medicines at the same time? 
Yes No 
  
27. Do you take supplements? 
Yes No 
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28. Do you take your supplements and your HIV medicines at the same time? 
Yes No 
  
29. Do you think it is necessary you take your HIV medicines every day? 
Yes No 
  
30. Do you think the HIV medicines you take can really keep you healthy? 
Yes No 
  
31. Did you ever stop taking your HIV medicines after taking it for a long time, like 2 to 3 
years? 
Yes No 
  
32. Did you tell any of your family members your HIV status? 
Yes No 
  
33. If yes, do your family members encourage you to always take your HIV medicines? 
Yes No 
  
34. Whenever you fall sick do you receive enough care and assistance from your family?   
Yes No 
  
35. Do you get financial assistance from your family when you need it to transport yourself to 
the clinic? 
Yes No 
  
36. Do you experience any form of discrimination from your family or friends? 
Yes No 
  
37. If your answer to the above question is yes, please specify the kind of discrimination you 
experience? 
 
They don’t share cutleries 
with me 
They don’t like interacting 
with me 
Others (Please specify) 
   
38. Do you have diabetes? 
Yes No 
  
39. When were you diagnosed with diabetes? 
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Before I was 
diagnosed with HIV 
About the same 
time I was 
diagnosed with HIV 
About 6 months 
after I started taking 
medicines for HIV 
Longer than 6 
months after I 
started taking 
medicines for HIV 
    
40. Are you receiving medicines for diabetes? 
Yes No 
  
41. Are you receiving your medicines for diabetes in this hospital? 
Yes No 
  
42. After starting your diabetic treatment do you feel better than before? 
Yes No 
  
43. After starting your diabetic treatment do you feel worse than before? 
Yes No 
  
44. Do you sometimes not take your medicines for diabetes?                        
Yes No 
  
45. Do they usually check your blood sugar in the hospital? 
Yes No 
  
46. How often do the check your blood sugar in the hospital? 
 
Every visit After some visit Rarely Never 
    
47. When they check your blood sugar how often is your blood sugar high? 
 
Never Rarely Sometimes Most times Always I don’t 
know 
      
48. Are there some food or drinks you were asked not to eat or drink much? 
Yes No 
  
49. If your answer to the above question (number 50) is YES, do you obey the instruction? Yes     
No 
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ANNEXURE 5: APPROVAL FROM PROVINCIAL DEPARTMENT OF HEALTH 
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ANNEXURE 6: FACILITIES APPROVALS 
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ANNEXURE 7: ETHICS CERTIFICATE 
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ANNEXURE 8: PAPER 1 EVIDENCE OF SUBMISSION TO JOURNAL 
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ANNEXURE  9: PAPER 2 EVIDENCE OF SUBMISSION TO JOURNAL 
(MANUSCRIPT UNDER REVIEW) 
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ANNEXURE 10: PAPER 3 JOURNAL ACCEPTANCE LETTER  
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ANNEXURE 11: PAPER 4 EVIDENCE OF SUBMISSION OF REVISED MANUSCRIPT 
TO      JOURNAL 
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ANNEXURE 12: TURNITIN REPORT 
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